Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA. Andresen NK, et al. Among authors: lingjaerde oc. J Immunother Cancer. 2024 Jan 19;12(1):e007990. doi: 10.1136/jitc-2023-007990. J Immunother Cancer. 2024. PMID: 38242720 Free PMC article. Clinical Trial.
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.
Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T. Naume B, et al. Among authors: lingjaerde oc. Mol Oncol. 2007 Sep;1(2):160-71. doi: 10.1016/j.molonc.2007.03.004. Epub 2007 Apr 4. Mol Oncol. 2007. PMID: 19383292 Free PMC article.
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment.
Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø; OSBREAC; Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN. Tekpli X, et al. Nat Commun. 2019 Dec 3;10(1):5499. doi: 10.1038/s41467-019-13329-5. Nat Commun. 2019. PMID: 31796750 Free PMC article.
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O. Haugen MH, et al. Among authors: lingjaerde oc. JCO Precis Oncol. 2021 Jan 28;5:PO.20.00086. doi: 10.1200/PO.20.00086. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036235 Free PMC article. Clinical Trial.
Combining gene signatures improves prediction of breast cancer survival.
Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC. Zhao X, et al. Among authors: lingjaerde oc. PLoS One. 2011 Mar 10;6(3):e17845. doi: 10.1371/journal.pone.0017845. PLoS One. 2011. PMID: 21423775 Free PMC article.
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt; Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y. Sas-Chen A, et al. EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198. Print 2016 Sep. EMBO Mol Med. 2016. PMID: 27485121 Free PMC article.
167 results